CClinicalTrials.gg
RecruitingNCT07188597Updated Apr 13, 2026

Culturally Adapted Cognitive Behavior Therapy for Individuals At Risk of First Episode Psychosis

An interventional study of Cognitive Behavior Therapy for those at risk of first episode psychosis in Individuals at Risk of First Episode Psychosis, sponsored by Pakistan Institute of Living and Learning. Recruiting at 2 sites in Pakistan. Open to participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Pakistan Institute of Living and Learning · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
16 Years to 35 Years
Sex
All
01

Study summary

Young people constitute nearly half of Pakistan's population and are highly vulnerable to risk factors for mental illness, including poverty, inequality, abuse, and violence. Estimates suggest that 19-34% of children and adolescents experience emotional or behavioural disorders, though this is likely underestimated. In recent years, research has focused on those at imminent risk of developing serious conditions such as first episode psychosis. The concept of an At-Risk Mental State (ARMS) has highlighted the urgent need for interventions that address current symptoms, improve functioning, and reduce transition to psychosis.

Up to 80% of young people with ARMS have another diagnosable condition, and almost half show poor psychosocial outcomes even six years after initial help-seeking. Evidence demonstrates that early identification and treatment can delay or prevent psychosis, including severe and enduring illnesses like schizophrenia. Cognitive Behaviour Therapy (CBT) is among the most effective evidence-based approaches for this group. However, existing evidence comes largely from high-income countries, raising concerns about cultural applicability in low-resource settings.

This study will culturally adapt and field test a manualised CBT intervention for young people at risk of first episode psychosis. To our knowledge, this is the first such study in a low-income country. Findings will inform scalable, culturally relevant interventions for Pakistan and similar contexts.

Read the detailed description

Aims and Objectives:

The study has following aims and objectives:

  1. To culturally adapt the existing Cognitive Behavior Therapy for those at risk of first episode psychosis- "evidence-based therapy for people with ARMS" (Van der Gaag, et al., 2013).
  2. To field test the culturally adapted intervention in a randomised controlled trial
  3. To check whether adapted intervention reduces or delay the rates or incidence of transition from ARMS to first episode psychosis;
  4. To check whether adapted intervention improves other symptoms such as depression, anxiety and/or level of functioning in ARMS
  5. To explore the pereceived usefulness of intervention including perceived barriers and facilitators from different stakeholders' perspective.

Feasibility and acceptability of the intervention is defined as:

  • Recruitment rates, attendance (attending more than 70% of intervention sessions)
  • Acceptability of the intervention (based on participants satisfaction, attendance, attrition rates)
  • Completeness of assessment tools and the assessment schedule by participants

    • Preliminary efficacy of the intervention
02

Conditions studied

  • Individuals at Risk of First Episode Psychosis
03

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female help-seeking individual aged 16-35 years;
  • Score 6 or above on PQ-16
  • Meet the at risk of FEP criteria using CAARMS Operationalized Intake Criteria based on three groups (vulnerability, attenuated psychosis or brief limited intermittent psychotic symptoms group);
  • Assessed as competent to provide informed consent.
  • Give written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Temporary resident unlikely to be available for follow up.
  • Unable to engage, participate or respond to research questionnaires.
  • a history of psychotic illness (treated or untreated).
  • previous treatment with an antipsychotic or mood-stabilising agent.
  • active substance abuse (except nicotine or caffeine) or dependence within the last three months, according to DSM-V criteria.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavior Therapy for those at risk of first episode psychosis

    The participants in the intervention group will receive a culturally adapted manualised cognitive behavioral therapy (CBT). The interventions aim to reduce symptoms, normalises psychosis-like experiences and prevents a catastrophic appraisal of the psychotic-like symptoms from occurring

    Behavioral: Cognitive Behavior Therapy for those at risk of first episode psychosis

  • No intervention
    Treatment as Usual

    Treatment As Usual (TAU): Local medical, psychiatric and primary care services provide standard routine care according to their clinical judgment and available resources. These participants will receive an initial assessment along with TAU as ascertained by their treating doctor at the hospital. In current practice, individuals with ARMS (at risk of first episode psychosis) are not routinely referred to any psychological service in Pakistan. TAU in Pakistan largely comprises of pharmacotherapy. Research staff will record the nature and intensity of the routine care delivered for each participant.

Interventions

  • BehavioralCognitive Behavior Therapy for those at risk of first episode psychosis

    Participants will receive a culturally adapted manualised Cognitive Behavioural Therapy (CBT) for those at risk of first episode psychosis (FEP). The intervention aims to reduce symptoms, normalise psychosis-like experiences, and prevent catastrophic appraisals that may lead to delusions. It integrates psychoeducation, behavioural experiments, and techniques addressing cognitive biases. By reframing unusual experiences as perceptual or reasoning biases, distress and emotional arousal are reduced, lowering the chance of fixed, frightening beliefs. Homework tasks further support coping. CBT for At-Risk Mental States has shown effectiveness in reducing transition to psychosis and improving recovery. This study will adapt and field test the manual, with potential for remote delivery via phone, video, or AI tools to enhance accessibility.

    Also known as: CBT-FEP

05

What researchers measure

Primary outcomes

  1. Feasibility Indicator

    feasibility will be determined by collecting data on recruitment and retention rates, The success criterion of feasibility will be to recruit \> 50% of eligible participants

    Time frame: From baseline to 12th week (end of intervention)

  2. Acceptability Indicator

    Intervention acceptability will be assessed using data on attendance. Criterion for acceptability is a mean attendance rate of \>70%.

    Time frame: From baseline to 12th week (end of intervention)

Other outcomes

  1. The Prodromal Questionnaire

    A brief 16-item self-report screening questionnaire assesses the presence of attenuated psychotic symptoms on a two-point scale (true/false) followed by a 4-point distress rating for each item. A cut of 6 or above considered for further assessment to confirm at risk criteria

    Time frame: From baseline to 12th week (end of intervention)

  2. Brief-Comprehensive Assessment of At-Risk Mental States

    A semi-structured interview that assists in the identification of individuals at risk of developing a first-episode psychotic disorder.

    Time frame: From baseline to 12th week (end of intervention)

  3. Client Satisfaction Questionnaire

    The participants will rate their satisfaction with treatment at 3 months (after completion of the intervention) using the CSQ

    Time frame: From baseline to 12th week (end of intervention)

  4. Calgary Depression Scale

    The Calgary Depression Scale for Schizophrenia (CDSS) is a depression rating scale especially developed for assessing depression in schizophrenia. Higher score shows higher depression

    Time frame: From baseline to 12th week (end of intervention)

  5. Health Related Quality of Life EQ-5D-5L

    The EQ-5D is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response categories corresponding to no problems, some problems, and extreme problems

    Time frame: From baseline to 12th week (end of intervention)

  6. Generalized Anxiety Disorder (GAD-7)

    GAD-7 is a brief scale to identify probable cases of generalised anxiety and depression, as well as assessing symptom severity. Higher scores shows greator severity of anxiety

    Time frame: From baseline to 12th week (end of intervention)

  7. Social and Occupational Functioning Scale (SOFAS)

    SOFAS will be used to assess overall functioning in a single score (0-100). It is a global rating of current functioning; this instrument focuses on social and occupational functioning that is independent of the overall severity of the individual's psychological symptoms.

    Time frame: From baseline to 12th week (end of intervention)

  8. Brief Illness Perception Questionnaire

    a nine-item scale designed to rapidly assess the cognitive and emotional representations of illness

    Time frame: From baseline to 12th week (end of intervention)

  9. Kessler Psychological Distress Scale

    Level of distress will be assessed using a 10-item scale the "Kessler Psychological Distress Scale

    Time frame: From baseline to 12th week (end of intervention)

06

Study locations

2 of 2 sites recruiting
  • Commuity/Schools/Colleges
    Karachi, Sindh, Pakistan
    Recruiting
  • Karwan e Hayat
    Karachi, Sindh, Pakistan
    Recruiting
07

Registry details

Key details

Study ID
NCT07188597
Lead sponsor
Pakistan Institute of Living and Learning
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jan 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Ameer B Khoso, PhD Fellow
Contact
ameer.bukhsh@pill.org.pk
009235871845
Ameer B Khoso, PhD
principal investigator · Pakistan Institute of Living and Learning

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion